Our unique combination of science and engineering expertise is core to our offering at each stage of a product’s development and manufacturing cycle. Working closely with clients from design onwards, we can create optimized formulations with the greatest chances of therapeutic and commercial success.
Lonza has multiple technologies and approaches for modifying the behavior of drug compounds within the body to achieve:
Intrinsically enteric capsule technologies represent a significant breakthrough in providing enteric protection and targeted delivery. Capsules are designed for gastric protection, stomach protection against gastric-irritating compounds, and/or protection of the API from stomach acidity.
By incorporating biopharmaceutically-approved enteric polymers into the hard capsule shell, the technologies eliminate the need for enteric / delayed release coatings, and offer a number of benefits:
In addition to our intrinsically enteric capsule technologies, we have an extensive track record using various polymers and polymer combinations to achieve enteric protection, delayed release, and targeted delivery in the GI tract. The technologies used for targeted delivery are often employed in conjunction with other enabling technologies – such as solubility enhancement – in the development of complex dosage forms:
Lonza offers a full range of finished dosage forms focused on delayed, controlled and targeted release. These can range from single or multi-layer tablets, osmotic tablets, drug-layered or matrixed multiparticulates, capsules-in-capsules, and coated or uncoated capsules including liquid filled hard capsules (LFHC). LFHCs using either pH 6.8-7.2-triggered coatings or a combination of high pH-triggered and enzymatic-triggered coatings are typically used for effective colonic delivery.